Recent developments have convinced many that the DEA will seek to transfer cannabis to schedule III of the Controlled Substances Act soon. Yet the mechanics of the administrative process and the implications of the proposed change are not well understood. Our panel will discuss the role of other federal agencies in the scheduling review process, the legal implications of cannabis’s scheduling status under federal law, and the implications rescheduling would have for state-regulated cannabis markets, FDA enforcement, and more.
Intoxicating hemp cannabinoids are the source of a growing tide of lawsuits. Learn who the litigants are, why they want or don't want these products sold, what jurisdictions are feeling the brunt of the fight, and where the fight seems to be heading next.
As cannabis legalization sweeps across the United States, legislators, regulators, and the industry must improve and mesh future state and federal adult-use policy, armed with lessons from states that pioneered adult-use programs. Learn what worked and what must change.
Learn about the legal implications of new anti-discrimination protections for employees who consume cannabis, the use of "impairment expert" roles, and how employers can continue to enforce drug-free workplace policies while not violating cannabis use nondiscrimination laws.
Lawsuits around the country based on a constitutional principle referred to as the "dormant Commerce Clause" have upended the cannabis industry over the past two years. We will discuss the merits of these cases and how they may impact the shape and trajectory of the industry.
A discussion of the how rescheduling, the potential end of 280E, and the SAFER Banking Act will impact the currently moribund cannabis financing and mergers and acquisitions.
Distinguished labor law practitioners will lead a lively discussion of the key labor law concepts and issues every cannabis lawyer should understand, from the National Labor Relations Act to Labor Peace Agreements.
Designed to counter drug trafficking, money laundering, and other financial crimes, the Corporate Transparency Act poses particular challenges for the cannabis industry, such as fully disclosing beneficial owners in an industry still prohibited under federal law.
As cannabis is incorporated in healthcare, providers and patients face new legal challenges in everything from licensing, payors, and accreditation hurdles, to DEA registrations, controlled-substance prescribing rules, fraud, right-to-try laws, and FDA oversight. With anticipation of rescheduling of cannabis to Schedule III substance, there will be a discussion on how it impacts healthcare delivery, patient access and provider liability issues.